Literature DB >> 20822590

Potential for nosocomial transmission of multidrug-resistant (MDR) tuberculosis in a South African tertiary hospital.

Colleen M Bamford1, Jantjie J Taljaard.   

Abstract

BACKGROUND: Tuberculosis (TB) is a major health problem in the Western Cape, with an incidence exceeding 900 per 100 000 people. Nosocomial transmission of TB, and particularly drug-resistant TB, is a potential risk that may be undetected. Rapid diagnosis and rapid institution of effective anti-TB treatment, combined with appropriate infection control measures, are essential to prevent nosocomial transmission of TB. To estimate the potential for nosocomial transmission, we aimed to determine the in-hospital delays in diagnosis and treatment of patients with multidrug-resistant (MDR)-TB at a tertiary care hospital.
METHODS: A descriptive study, based on retrospective review of patient records and laboratory data, including all adult patients (>13 years) where TB culture and susceptibility testing confirmed MDR- TB on specimens submitted to Tygerberg Hospital's National Health Laboratory Service (NHLS) laboratory in 2007.
RESULTS: Thirty-one patients with MDR-TB were identified. The median laboratory turnaround time (TAT) from collection of specimen to confirmation of MDR-TB was 40 days, while the median time from the time of first presentation at Tygerberg Hospital to institution of MDR treatment was 44 days. Twenty patients were considered infectious during their hospital stay, generating 345 inpatient infectious days.
CONCLUSIONS: The study suggests that there is an ongoing substantial risk for nosocomial transmission of MDR-TB at Tygerberg Hospital. We propose improvements, including the use of rapid drug susceptibility testing. The consistent application of infection control measures to prevent nosocomial spread of TB, including MDR-TB, remains vital.

Entities:  

Mesh:

Year:  2010        PMID: 20822590     DOI: 10.7196/samj.3501

Source DB:  PubMed          Journal:  S Afr Med J


  6 in total

1.  Effects of introducing Xpert MTB/RIF test on multi-drug resistant tuberculosis diagnosis in KwaZulu-Natal South Africa.

Authors:  Nomonde R Dlamini-Mvelase; Lise Werner; Rogerio Phili; Lindiwe P Cele; Koleka P Mlisana
Journal:  BMC Infect Dis       Date:  2014-08-16       Impact factor: 3.090

2.  Evaluation of tuberculosis infection control measures implemented at primary health care facilities in Kwazulu-Natal province of South Africa.

Authors:  Ntambwe Malangu; Michah Mngomezulu
Journal:  BMC Infect Dis       Date:  2015-03-07       Impact factor: 3.090

3.  Assessing the utility of Xpert(®) MTB/RIF as a screening tool for patients admitted to medical wards in South Africa.

Authors:  Christine L Heidebrecht; Laura J Podewils; Alexander S Pym; Ted Cohen; Thuli Mthiyane; Douglas Wilson
Journal:  Sci Rep       Date:  2016-01-20       Impact factor: 4.379

4.  Towards understanding the drivers of policy change: a case study of infection control policies for multi-drug resistant tuberculosis in South Africa.

Authors:  Trust Saidi; Faatiema Salie; Tania S Douglas
Journal:  Health Res Policy Syst       Date:  2017-05-30

5.  The effect of the Xpert MTB/RIF test on the time to MDR-TB treatment initiation in a rural setting: a cohort study in South Africa's Eastern Cape Province.

Authors:  Joshua Iruedo; Don O'Mahony; Sikhumbuzo Mabunda; Graham Wright; Busisiwe Cawe
Journal:  BMC Infect Dis       Date:  2017-01-21       Impact factor: 3.090

6.  Tuberculosis in healthcare workers and infection control measures at primary healthcare facilities in South Africa.

Authors:  Mareli M Claassens; Cari van Schalkwyk; Elizabeth du Toit; Eline Roest; Carl J Lombard; Donald A Enarson; Nulda Beyers; Martien W Borgdorff
Journal:  PLoS One       Date:  2013-10-02       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.